Researchers To Tackle New Macular Degeneration Target Using Antisense
This article was originally published in Start Up
Executive Summary
A research team has identified a way to treat the dry form of advanced age-related macular degeneration, for which no therapy exists to halt the associated vision loss. The team expects to start clinical testing of an antisense compound to address the problem, an accumulation of a type of RNA, by the end of the year.